Cytokinetics
CYTK
A$56.14
Share price
-1.48%
Change (1 day)
-37.75%
Change (1 year)
Categories
P/S ratio for Cytokinetics (CYTK)
P/S ratio as of July 2025 (TTM): 228
According to Cytokinetics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -16.4. At the end of 2025 the company had a P/S ratio of 266.
P/S ratio history for Cytokinetics from 2004 to 2025
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2025 | 266 | -12.04% |
| 2024 | 303 | -72.17% |
| 2023 | > 1000 | 2271.65% |
| 2022 | 45.8 | -16.07% |
| 2021 | 54.6 | 107.32% |
| 2020 | 26.3 | 12.75% |
| 2019 | 23.4 | 112.85% |
| 2018 | 11.0 | -66.58% |
| 2017 | 32.9 | 608.37% |
| 2016 | 4.64 | -67.9% |
| 2015 | 14.4 | 118.99% |
| 2014 | 6.60 | 1.38% |
| 2013 | 6.51 | -47.69% |
| 2012 | 12.4 | -28.3% |
| 2011 | 17.3 | -68.04% |
| 2010 | 54.3 | 2382.3% |
| 2009 | 2.19 | -80.92% |
| 2008 | 11.5 | -33.03% |
| 2007 | 17.1 | -83.47% |
| 2006 | 104 | 425.56% |
| 2005 | 19.7 | -3.76% |
| 2004 | 20.5 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Ligand Pharmaceuticals LGND | 14.3 | -93.70% | 🇺🇸 USA |
 Trevena TRVN | 0.3955 | -99.83% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | 0.0071 | -100.00% | 🇺🇸 USA |
 Amgen AMGN | 4.75 | -97.91% | 🇺🇸 USA |
 Array Technologies ARRY | 1.01 | -99.56% | 🇺🇸 USA |